pmid	doi	year	title	Hugo_Symbol
34162179	10.3324/haematol.2021.278743	2022	Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.	EZH2
34382383	10.3324/haematol.2020.263251	2022	Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.	EZH2
34601504	10.1038/s41379-021-00938-z	2022	Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.	EZH2
34655667	10.1016/j.canlet.2021.10.010	2022	EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.	EZH2
34788984	10.3324/haematol.2021.279177	2022	Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.	EZH2
34793663	10.4143/crt.2021.1121	2022	Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma.	EZH2
34837284	10.1111/cas.15224	2022	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.	EZH2
34904909	10.1080/14656566.2021.2014815	2022	Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.	EZH2
34957565	10.1002/path.5861	2022	Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma.	EZH2
35022084	10.1186/s13046-021-02234-9	2022	The follicular lymphoma epigenome regulates its microenvironment.	EZH2
35031597	10.1038/s41420-022-00819-7	2022	ALKBH5-mediated N<sup>6</sup>-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation.	EZH2
35034955	10.1038/s41375-021-01494-w	2022	Inhibition of theÂ deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.	EZH2
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	EZH2
35082399	10.1038/s41417-021-00415-4	2022	CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.	EZH2
35086959	10.1158/1535-7163.MCT-21-0216	2022	Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.	EZH2
35151584	10.1016/j.clml.2021.12.014	2022	Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.	EZH2
35157216	10.1007/s12325-022-02054-z	2022	A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.	EZH2
35173526	10.7150/ijbs.64752	2022	SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.	EZH2
35180337	10.46883.2022.25920946	2022	Follicular Lymphoma: a Focus on Current and Emerging Therapies	EZH2
35181615		2022	Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.	EZH2
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	EZH2
35247900	10.1158/2643-3230.BCD-21-0098	2022	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.	EZH2
35250278	10.2147/OTT.S267011	2022	Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.	EZH2
35253299	10.1002/gcc.23036	2022	CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.	EZH2
35357654	10.1007/s13402-022-00663-y	2022	BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.	EZH2
35369397	10.6004/jadpro.2022.13.2.7	2022	Tazemetostat: EZH2 Inhibitor.	EZH2
35379077	10.1080/10428194.2022.2057488	2022	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.	EZH2
35380993	10.1172/JCI145343	2022	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma.	EZH2
35454811	10.3390/cancers14081904	2022	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	EZH2
35491222	10.11406/rinketsu.63.313	2022	[Epigenetic modification as a therapeutic approach for B-cell lymphoma].	EZH2
35522148	10.3324/haematol.2021.280005	2022	Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas.	EZH2
35561310	10.1182/bloodadvances.2021006069	2022	Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment.	EZH2
35562412	10.1038/s41379-022-01085-9	2022	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.	EZH2
35574216	10.18632/oncotarget.28229	2022	Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes.	EZH2
35650206	10.1038/s41467-022-30651-7	2022	Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.	EZH2
35661922	10.1007/s00428-022-03347-y	2022	H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas.	EZH2
35734596	10.3389/fonc.2022.846573	2022	The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China.	EZH2
35753676	10.1016/j.bbagrm.2022.194840	2022	Chemical biology and pharmacology of histone lysine methylation inhibitors.	EZH2
35772421	10.1016/S2352-3026(22)00169-7	2022	Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma.	EZH2
35772429	10.1016/S2352-3026(22)00134-X	2022	SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.	EZH2
35795062	10.3389/fonc.2022.870487	2022	Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.	EZH2
35851487	10.1016/j.blre.2022.100988	2022	Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.	EZH2
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	EZH2
35941836	10.1080/15384101.2022.2109898	2022	ELK1-Induced upregulation of long non-coding TNK2-AS1 promotes the progression of acute myeloid leukemia by EZH2-mediated epigenetic silencing of CELF2.	EZH2
35959380	10.2147/BLCTT.S282247	2022	A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?	EZH2
35960849	10.1182/blood.2022016428	2022	Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma.	EZH2
35973200	10.1182/bloodadvances.2022008403	2022	Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation.	EZH2
36029326	10.1007/s00277-022-04914-8	2022	Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.	EZH2
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	EZH2
32799209	10.1159/000509159	2021	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.	EZH2
32855278	10.3324/haematol.2020.254854	2021	Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.	EZH2
33094664	10.1080/15476286.2020.1838783	2021	LncRNAs in adaptive immunity: role in physiological and pathological conditions.	EZH2
33226554	10.1007/s12094-020-02504-6	2021	Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma.	EZH2
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	EZH2
33270606	10.1172/JCI135711	2021	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.	EZH2
33271120	10.1016/j.immuni.2020.11.002	2021	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.	EZH2
33389794	10.1002/jcla.23693	2021	USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.	EZH2
33413063	10.2174/1568009620666210106122750	2021	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).	EZH2
33414134	10.1158/1078-0432.CCR-20-2378	2021	Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.	EZH2
33431788	10.1038/s41392-020-00437-8	2021	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	EZH2
33436855	10.1038/s41598-020-80613-6	2021	Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia.	EZH2
33492746	10.1111/cas.14822	2021	Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.	EZH2
33502806	10.1002/biof.1704	2021	BCL-6 promotes the methylation of miR-34a by recruiting EZH2 and upregulating CTRP9 to protect ischemic myocardial injury.	EZH2
33513156	10.1371/journal.pone.0237554	2021	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.	EZH2
33529029	10.1021/acs.jmedchem.0c02112	2021	Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug.	EZH2
33560380	10.1182/bloodadvances.2020002469	2021	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.	EZH2
33562694	10.3390/cancers13040641	2021	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.	EZH2
33616890	10.1007/s40265-020-01446-1	2021	Novel Therapy Approaches to Follicular Lymphoma.	EZH2
33709777	10.2217/fon-2020-1244	2021	EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.	EZH2
33711241	10.1080/14656566.2021.1902988	2021	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.	EZH2
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	EZH2
33754292	10.1007/s11899-021-00614-8	2021	Targeted Therapies for Follicular Lymphoma.	EZH2
33770460	10.1200/EDBK_320117	2021	Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.	EZH2
33792119	10.1111/cas.14905	2021	CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.	EZH2
33794893	10.1186/s12935-021-01897-w	2021	Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells.	EZH2
33797691	10.1007/s11899-021-00617-5	2021	When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.	EZH2
33821477	10.1002/ijc.33584	2021	A rare variant in EZH2 is associated with prostate cancer risk.	EZH2
33829512	10.1111/his.14378	2021	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	EZH2
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	EZH2
33904892	10.1182/bloodadvances.2020002773	2021	Treating lymphoma is now a bit EZ-er.	EZH2
33935039	10.5045/br.2021.2021049	2021	Genomics of diffuse large B cell lymphoma.	EZH2
33937922	10.1007/s11912-021-01076-0	2021	Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.	EZH2
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-ÎºB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	EZH2
33997750	10.1016/j.jhepr.2021.100276	2021	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.	EZH2
34017197	10.2147/CMAR.S267258	2021	Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.	EZH2
34044429	10.24875/RIC.21000070	2021	A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.	EZH2
34065087	10.3390/ijms22095013	2021	The Impact of Epigenetic Modifications in Myeloid Malignancies.	EZH2
34069564	10.3390/ijms22105352	2021	The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.	EZH2
34094676		2021	HMGA1 induces EZH2 overexpression in human B-cell lymphomas.	EZH2
34104370	10.1177/20406207211015882	2021	The role of tazemetostat in relapsed/refractory follicular lymphoma.	EZH2
34105464	10.19746/j.cnki.issn.1009-2137.2021.03.012	2021	[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].	EZH2
34159682	10.1111/cas.15040	2021	Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.	EZH2
34168051	10.1158/1078-0432.CCR-20-4027	2021	Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.	EZH2
34193230	10.1186/s13045-021-01113-2	2021	Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.	EZH2
34196564	10.1021/acs.jmedchem.1c00460	2021	Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma.	EZH2
34202528	10.3390/cancers13133155	2021	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.	EZH2
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	EZH2
34321240	10.1158/0008-5472.CAN-21-1027	2021	Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL.	EZH2
34351144	10.1021/acs.jmedchem.1c00226	2021	Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.	EZH2
34376807	10.1038/s41379-021-00885-9	2021	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.	EZH2
34449935	10.1111/cas.15122	2021	The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.	EZH2
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	EZH2
34478526	10.1182/bloodadvances.2021005215	2021	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.	EZH2
34488340	10.1021/acs.jmedchem.1c01116	2021	Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.	EZH2
34503063	10.3390/cancers13174249	2021	The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma.	EZH2
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	EZH2
34590470	10.52586/4970	2021	Methylation alterations and advance of treatment in lymphoma.	EZH2
34664960	10.1021/acs.jmedchem.1c01154	2021	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.	EZH2
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	EZH2
34781267	10.6004/jnccn.2021.0054	2021	NCCN GuidelinesÂ® Insights: B-Cell Lymphomas, Version 5.2021.	EZH2
34807608	10.1021/acs.jmedchem.1c01161	2021	Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.	EZH2
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	EZH2
34944658	10.3390/biomedicines9121842	2021	Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas.	EZH2
34945856	10.3390/jpm11121384	2021	Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.	EZH2
35008680	10.3390/ijms23010253	2021	Histone Modifications and Their Targeting in Lymphoid Malignancies.	EZH2
35071240	10.3389/fcell.2021.805195	2021	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.	EZH2
30842630	10.1038/s41423-019-0219-z	2020	The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection.	EZH2
31289198	10.3324/haematol.2019.222935	2020	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.	EZH2
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	EZH2
31637838	10.1002/cyto.a.23919	2020	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity.	EZH2
31680297	10.1002/ajh.25673	2020	Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.	EZH2
31685780	10.1248/cpb.c19-00550	2020	Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.	EZH2
31752573	10.1080/10428194.2019.1691200	2020	New murine models of aggressive lymphoma.	EZH2
31819273	10.1038/s41589-019-0421-4	2020	Discovery of a first-in-class EZH2 selective degrader.	EZH2
31831267	10.1016/j.chembiol.2019.11.006	2020	Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.	EZH2
31846764	10.1016/j.jprot.2019.103614	2020	Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.	EZH2
31891210	10.1002/hon.2711	2020	Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.	EZH2
31962268	10.1016/j.molimm.2020.01.006	2020	EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.	EZH2
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	EZH2
32027840	10.1016/j.molcel.2020.01.017	2020	Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters.	EZH2
32122924	10.1158/1078-0432.CCR-19-3741	2020	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.	EZH2
32138178	10.3390/cancers12030580	2020	Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells.	EZH2
32139296	10.1016/j.clml.2019.11.007	2020	Defining Acute Myeloid Leukemia Ontogeny in Older Patients.	EZH2
32166598	10.1007/s40265-020-01288-x	2020	Tazemetostat: First Approval.	EZH2
32232478	10.1182/bloodadvances.2019001256	2020	Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma.	EZH2
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	EZH2
32349972	10.1158/2159-8290.CD-19-0789	2020	<i>EZH2</i>-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress.	EZH2
32396854	10.1016/j.ccell.2020.04.008	2020	Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma.	EZH2
32396861	10.1016/j.ccell.2020.04.004	2020	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.	EZH2
32408898	10.1186/s12885-020-06937-8	2020	Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.	EZH2
32421389	10.1200/JOP.19.00691	2020	Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma.	EZH2
32421455	10.1200/EDBK_279043	2020	ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.	EZH2
32512858	10.3390/cancers12061464	2020	The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth.	EZH2
32525136	10.1358/dot.2020.56.6.3147937	2020	Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.	EZH2
32533097	10.1038/s41388-020-1347-8	2020	The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.	EZH2
32546039	10.1080/10428194.2020.1775216	2020	TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.	EZH2
32552947	10.19746/j.cnki.issn.1009-2137.2020.03.022	2020	[Expression and Clinical Significance of EZH2 in Patients with Diffuse Large B Cell Lymphoma Accompanied by HBV Infection].	EZH2
32580550	10.1021/acs.jmedchem.0c00479	2020	EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.	EZH2
32601883	10.1007/s11864-020-00761-9	2020	Hypomethylating Agents in Lymphoma.	EZH2
32641029	10.1186/s12906-020-03006-2	2020	Matrine inhibits the growth of natural killer/T-cell lymphoma cells by modulating CaMKIIÎ³-c-Myc signaling pathway.	EZH2
32668764	10.3390/genes11070785	2020	Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.	EZH2
32715799	10.1080/10428194.2020.1795155	2020	<i>EZH2</i>-activating mutation: no reliable indicator for efficacy of methyltransferase inhibitors.	EZH2
32715803	10.1080/14740338.2020.1802424	2020	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.	EZH2
32788174	10.1158/1055-9965.EPI-20-0451	2020	Stochastic Epigenetic Mutations Are Associated with Risk of Breast Cancer, Lung Cancer, and Mature B-cell Neoplasms.	EZH2
32816857	10.1158/0008-5472.CAN-20-1259	2020	SUMOylation of E2F1 Regulates Expression of EZH2.	EZH2
32850364	10.3389/fonc.2020.01226	2020	Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of <i>cdkn2b</i>.	EZH2
32853382	10.1182/bloodadvances.2019000938	2020	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.	EZH2
32906688	10.3390/cancers12092541	2020	Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in <i>EZH2</i> Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma.	EZH2
32978169	10.1158/0008-5472.CAN-20-2147	2020	EZH2-Targeted Therapies in Cancer: Hype or a Reality.	EZH2
33035457	10.1016/S1470-2045(20)30441-1	2020	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.	EZH2
33035458	10.1016/S1470-2045(20)30530-1	2020	EZH2 inhibition for epithelioid sarcoma and follicular lymphoma.	EZH2
33104794	10.1182/bloodadvances.2020002580	2020	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.	EZH2
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	EZH2
33233721	10.3390/ijms21228795	2020	Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.	EZH2
33283516	10.1021/acs.jmedchem.0c01344	2020	Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.	EZH2
33288562	10.21873/anticanres.14692	2020	EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.	EZH2
33374737	10.3390/ijms22010074	2020	Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.	EZH2
33843893		2020	Refining the management of relapsed or refractory follicular lymphoma.	EZH2
34365354	10.1158/2159-8290.CD-RW2020-150	2020	The EZH2 Inhibitor Tazemetostat Shows Efficacy in Follicular Lymphoma.	EZH2
34667996	10.21037/aol-20-20	2020	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	EZH2
30218753	10.1016/j.humpath.2018.08.025	2019	Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.	EZH2
30371509	10.1097/PAS.0000000000001180	2019	Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.	EZH2
30588655	10.1111/his.13815	2019	ALK and EGFR expression by immunohistochemistry are associated with Merkel cell polyomavirus status in Merkel cell carcinoma.	EZH2
30608448	10.1097/MD.0000000000014011	2019	Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.	EZH2
30705065	10.1158/2159-8290.CD-18-1090	2019	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.	EZH2
30719267	10.1177/2040620718820510	2019	Novel treatment approaches and future perspectives in follicular lymphoma.	EZH2
30788082	10.1016/j.csbj.2019.01.006	2019	Bivalent Ligands for Protein Degradation in Drug Discovery.	EZH2
30814291	10.1128/JVI.02143-18	2019	A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.	EZH2
30837715	10.1038/s41571-019-0190-8	2019	Emerging epigenetic-modulating therapies in lymphoma.	EZH2
30885427	10.1016/j.molmed.2019.02.013	2019	The 3D Genome: EZH2 Comes into the Fold.	EZH2
30935402	10.1186/s13045-019-0716-7	2019	Molecular pathogenic pathways in extranodal NK/T cell lymphoma.	EZH2
30936220	10.1158/2159-8290.CD-19-0090	2019	EZH2 Inhibitors: Take It EZy, It Is All About Context.	EZH2
30979734	10.1158/1078-0432.CCR-18-3989	2019	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.	EZH2
31000418	10.1016/j.ebiom.2019.03.083	2019	Assessment of epigenetic mechanisms and DNA double-strand break repair using laser micro-irradiation technique developed for hematological cells.	EZH2
31139703		2019	Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy.	EZH2
31142679	10.1126/scitranslmed.aau9087	2019	Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.	EZH2
31171828	10.1038/s41401-019-0248-2	2019	AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.	EZH2
31204938	10.19746/j.cnki.issn.1009-2137.2019.03.029	2019	[Expression of MiR101 and EZH2 in Patients with Mantle Cell Lymphoma and Its Clinical Significance].	EZH2
31205561	10.7150/jca.29807	2019	EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions.	EZH2
31205619	10.1016/j.csbj.2019.03.006	2019	Application of PD-1 Blockade in Cancer Immunotherapy.	EZH2
31219818	10.1097/PAS.0000000000001312	2019	Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.	EZH2
31287161	10.1002/cncr.32145	2019	Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?	EZH2
31295529	10.1016/j.bbadis.2019.07.001	2019	The regulation of NDRG2 expression during ATLL development after HTLV-1 infection.	EZH2
31322273	10.3892/or.2019.7240	2019	Growth inhibition and transcriptional effects of ribavirin in lymphoma.	EZH2
31366503	10.21873/anticanres.13577	2019	Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.	EZH2
31419226	10.1371/journal.pone.0220681	2019	DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.	EZH2
31423206	10.3892/ol.2019.10410	2019	Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.	EZH2
31434700	10.1182/blood.2019000381	2019	MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.	EZH2
31471312	10.1158/1078-0432.CCR-18-4121	2019	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.	EZH2
31492675	10.1182/blood.2019000015	2019	Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.	EZH2
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	EZH2
31565482	10.20892/j.issn.2095-3941.2018.0380	2019	Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma.	EZH2
31631594		2019	[Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].	EZH2
31681423	10.3389/fgene.2019.00986	2019	Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.	EZH2
31697821	10.1182/blood.2019002067	2019	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.	EZH2
31740676	10.1038/s41408-019-0249-x	2019	Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.	EZH2
31747604	10.1016/j.celrep.2019.10.083	2019	Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.	EZH2
31752930	10.1186/s13045-019-0814-6	2019	EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.	EZH2
31805195	10.1182/blood.2019003023	2019	The EZ-riding NK/T-cell lymphoma.	EZH2
28641467	10.1080/10428194.2017.1339881	2018	Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.	EZH2
29122756	10.1182/blood-2017-08-799080	2018	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.	EZH2
29158360	10.1182/blood-2017-08-737361	2018	Chromatin modifying gene mutations in follicular lymphoma.	EZH2
29200404	10.1172/JCI94509	2018	STAT5BN642H is a driver mutation for T cell neoplasia.	EZH2
29248547	10.1016/j.jid.2017.10.036	2018	Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.	EZH2
29363553	10.1042/BSR20171589	2018	Hematopoietic stem/progenitor cell senescence is associated with altered expression profiles of cellular memory-involved gene.	EZH2
29397836	10.7534/j.issn.1009-2137.2018.01.027	2018	[Significance of H3K27me3 and EZH2 in Predicting the Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma].	EZH2
29456795	10.1021/acsmedchemlett.7b00437	2018	Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.	EZH2
29473431	10.1080/10428194.2018.1430795	2018	Enhancer of zeste homolog 2 (EZH2) inhibitors.	EZH2
29572378	10.1182/blood-2017-08-804344	2018	Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.	EZH2
29616853	10.1080/10428194.2018.1443452	2018	Clonal shifts in MDS - from SF3B1 to EZH2.	EZH2
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	EZH2
29650362	10.1016/S1470-2045(18)30145-1	2018	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.	EZH2
29650364	10.1016/S1470-2045(18)30149-9	2018	Targeting EZH2 with tazemetostat.	EZH2
29663940		2018	EZH2 Expression in Naturally Occurring Canine Tumors.	EZH2
29669287	10.1016/j.celrep.2018.03.078	2018	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.	EZH2
29738334	10.1097/MOH.0000000000000437	2018	Precision medicine and lymphoma.	EZH2
29743404	10.11406/rinketsu.59.432	2018	[Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].	EZH2
29858685	10.1007/s00428-018-2384-3	2018	Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.	EZH2
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	EZH2
29970342	10.1016/j.clml.2018.06.004	2018	Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.	EZH2
29980507	10.1158/2159-8290.CD-NB2018-088	2018	Positive Results for Tazemetostat in Follicular Lymphoma.	EZH2
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	EZH2
30031020	10.1016/j.yexmp.2018.07.009	2018	EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes.	EZH2
30080177	10.1172/JCI94645	2018	Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.	EZH2
30087673	10.3389/fmicb.2018.01686	2018	HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia-Lymphoma.	EZH2
30112706	10.1007/s11899-018-0466-6	2018	Emerging EZH2 Inhibitors and Their Application in Lymphoma.	EZH2
30126979	10.1182/blood-2018-03-837252	2018	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.	EZH2
30159126	10.18632/oncotarget.25835	2018	LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL).	EZH2
30176648		2018	[INHIBITORY EZH2 NOWÄ OPCJÄ TERAPEUTYCZNÄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHÅONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].	EZH2
30258009	10.1128/JVI.00909-18	2018	Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2.	EZH2
30269902	10.1016/j.stem.2018.08.018	2018	Epigenetic Restoration of Fetal-like IGF1 Signaling Inhibits Leukemia Stem Cell Activity.	EZH2
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	EZH2
30404791	10.1084/jem.20180570	2018	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.	EZH2
31938438		2018	Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature.	EZH2
27184221	10.1080/10428194.2016.1180686	2017	Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.	EZH2
27389057	10.1038/leu.2016.175	2017	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.	EZH2
27555605	10.1002/pbc.26218	2017	Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.	EZH2
28092155	10.1021/acs.jmedchem.6b01576	2017	Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.	EZH2
28106467	10.1080/15592294.2017.1282587	2017	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.	EZH2
28122867	10.1158/2159-8290.CD-16-0330	2017	The Genetic Basis of Hepatosplenic T-cell Lymphoma.	EZH2
28135235	10.1038/nchembio.2304	2017	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.	EZH2
28167662	10.1182/blood-2016-09-741348	2017	Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.	EZH2
28229364	10.1007/s11864-017-0449-1	2017	Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.	EZH2
28249909		2017	Morphoproteomics Identifies SIRT1 and EZH2 Pathways as Commonalities in B-cell Acute Lymphoblastic Leukemia: Pathogenetic Implications and Opportunities for Therapeutic Intervention.	EZH2
28256832	10.1021/acs.jmedchem.7b00287	2017	Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).	EZH2
28359267	10.1186/s12885-017-3233-5	2017	Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.	EZH2
28411252	10.3324/haematol.2017.165415	2017	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.	EZH2
28412742	10.18632/oncotarget.15453	2017	Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma.	EZH2
28430172	10.1038/bcj.2017.32	2017	EZH2 alterations in follicular lymphoma: biological and clinical correlations.	EZH2
28438623	10.1016/j.humpath.2017.04.011	2017	EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.	EZH2
28487787	10.1155/2017/5083463	2017	EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in <i>ASXL1</i>, <i>BCOR</i>, <i>CDKN2A</i>, <i>NF1</i>, and <i>TP53</i>.	EZH2
28548121	10.1038/modpathol.2017.37	2017	EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.	EZH2
28556566	10.1002/pro.3202	2017	Select human cancer mutants of NRMT1 alter its catalytic activity and decrease N-terminal trimethylation.	EZH2
28625826	10.1016/j.addr.2017.06.010	2017	Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.	EZH2
28653353	10.1111/bjh.14803	2017	Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.	EZH2
28655885	10.1038/s41598-017-02800-2	2017	miR-15a/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin.	EZH2
28659443	10.1126/scitranslmed.aak9969	2017	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.	EZH2
28741798	10.1111/cas.13326	2017	Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.	EZH2
28747286	10.4274/tjh.2017.0194	2017	Coexistence of EZH2, NOTCH1, IL7R, and PHF6 Mutations in Adult T-cell Acute Lymphoblastic Leukemia.	EZH2
28811957	10.1080/2162402X.2017.1321184	2017	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.	EZH2
28835384	10.1158/1535-7163.MCT-16-0840	2017	EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.	EZH2
28914785	10.3390/ijms18091986	2017	Hsp90Î± Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.	EZH2
28976514	10.1039/c7fo00263g	2017	Role of epigenetic regulation on the induction of apoptosis in Jurkat leukemia cells by white grape pomace rich in phenolic compounds.	EZH2
28978842	10.11406/rinketsu.58.2004	2017	Molecular pathogenesis and its therapeutic implication for ATL.	EZH2
28993276	10.1016/j.humpath.2017.09.013	2017	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.	EZH2
29113202	10.3892/ol.2017.6912	2017	EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys<sup>27</sup> acetylation in the <i>BIM</i> gene promoter and enhancers.	EZH2
29113297	10.18632/oncotarget.17956	2017	Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex.	EZH2
29209652	10.1080/23723556.2017.1365107	2017	Sestrin1, a tumor suppressor that can be rescued.	EZH2
29222279	10.1182/asheducation-2017.1.358	2017	Follicular lymphoma: are we ready for a risk-adapted approach?	EZH2
32300390	10.14740/jh320w	2017	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.	EZH2
25893294	10.1038/onc.2015.114	2016	Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.	EZH2
26337274	10.1007/s13277-015-3977-y	2016	The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.	EZH2
26659825	10.1158/1541-7786.MCR-15-0313	2016	Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.	EZH2
26697989	10.1016/j.critrevonc.2015.11.004	2016	Myeloproliferative neoplasms: Current molecular biology and genetics.	EZH2
26698557	10.2217/epi.15.96	2016	Epigenetic dysregulation in follicular lymphoma.	EZH2
26757888	10.3109/10428194.2015.1121261	2016	Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.	EZH2
26769278	10.1021/acs.jmedchem.5b01501	2016	The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.	EZH2
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	EZH2
26773042	10.1182/blood-2015-08-662593	2016	Polycomb-dependent epigenetic landscape in adult T-cell leukemia.	EZH2
26883583	10.3109/10428194.2016.1139703	2016	Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.	EZH2
26904942	10.1016/j.celrep.2016.01.064	2016	Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.	EZH2
26917488	10.1111/bjh.13952	2016	Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.	EZH2
26973857	10.18632/oncoscience.288	2016	EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.	EZH2
27010137		2016	Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.	EZH2
27052808	10.1080/15592294.2016.1164375	2016	Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.	EZH2
27055146	10.1097/MOH.0000000000000249	2016	The many layers of epigenetic dysfunction in B-cell lymphomas.	EZH2
27086936	10.3109/10428194.2016.1165816	2016	Rubinstein-Taybi syndrome - a window into follicular lymphoma biology.	EZH2
27098631		2016	Extranodal B Cell Lymphoma with Prominent Spindle Cell Features Arising in Uterus and in Maxillary Sinus: Report of Two Cases and Literature Review.	EZH2
27102345	10.1038/modpathol.2016.79	2016	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	EZH2
27135738	10.1038/nm.4092	2016	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.	EZH2
27169594	10.1007/s00432-016-2174-8	2016	EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.	EZH2
27261606	10.1016/j.biopha.2016.04.019	2016	Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.	EZH2
27282353	10.1038/modpathol.2016.114	2016	Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.	EZH2
27289323	10.1016/j.bmcl.2016.05.018	2016	Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.	EZH2
27297789	10.1182/blood-2016-01-690701	2016	EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.	EZH2
27311868	10.1016/j.pathol.2016.05.002	2016	Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.	EZH2
27322685	10.18632/oncotarget.9982	2016	Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia.	EZH2
27440511	10.1373/clinchem.2016.255315	2016	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.	EZH2
27490482	10.7554/eLife.18270	2016	MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.	EZH2
27505670	10.1016/j.ccell.2016.07.006	2016	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.	EZH2
27548656	10.4155/fmc-2016-0096	2016	Recently discovered EZH2 and EHMT2 (G9a) inhibitors.	EZH2
27550047	10.4132/jptm.2016.06.06	2016	Long Non-coding RNA HOTAIR Expression in Diffuse Large B-Cell Lymphoma: In Relation to Polycomb Repressive Complex Pathway Proteins and H3K27 Trimethylation.	EZH2
27739677	10.1021/acs.jmedchem.6b01315	2016	Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.	EZH2
27748863	10.3892/or.2016.5147	2016	Role of HOTAIR in the diagnosis and prognosis of acute leukemia.	EZH2
27807891	10.1111/apm.12623	2016	Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.	EZH2
27888877	10.1016/j.hoc.2016.07.007	2016	Promising Novel Agents for Aggressive B-Cell Lymphoma.	EZH2
27889452	10.1016/j.molcel.2016.10.021	2016	An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences.	EZH2
27980305	10.3960/jslrt.56.71	2016	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.	EZH2
27998273	10.1186/s12967-016-1100-9	2016	LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.	EZH2
24469040	10.1038/onc.2013.571	2015	Oncogenic Y641 mutations in EZH2 prevent Jak2/Î²-TrCP-mediated degradation.	EZH2
25030036	10.3109/10428194.2014.944522	2015	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.	EZH2
25130477	10.3109/10428194.2014.941836	2015	Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.	EZH2
25263318	10.3109/10428194.2014.968780	2015	Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.	EZH2
25382618	10.3109/10428194.2014.983099	2015	Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype.	EZH2
25407652	10.3109/10428194.2014.987770	2015	EZH2: a potential new target in T-cell lymphoma?	EZH2
25568352	10.1182/blood-2014-10-606822	2015	Polycomb genes, miRNA, and their deregulation in B-cell malignancies.	EZH2
25586788	10.1002/cncr.29198	2015	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.	EZH2
25587943	10.1080/15592294.2014.1003746	2015	Epigenetic regulation in human melanoma: past and future.	EZH2
25595890	10.18632/oncotarget.2218	2015	Mutational spectrum of adult T-ALL.	EZH2
25605023	10.18632/oncotarget.3120	2015	HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.	EZH2
25651430	10.3109/10428194.2015.1006220	2015	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.	EZH2
25762637	10.18632/oncotarget.3154	2015	Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?	EZH2
25807917	10.1002/cncy.21535	2015	Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.	EZH2
26004134	10.1517/13543784.2015.1051220	2015	Targeting of cancer stem cells by inhibitors of DNA and histone methylation.	EZH2
26005520	10.1021/acsmedchemlett.5b00037	2015	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.	EZH2
26027790	10.1016/j.exphem.2015.05.001	2015	Targeting EZH2 and PRC2 dependence as novel anticancer therapy.	EZH2
26062053	10.1002/hon.2215	2015	VII. Are lymphomas driven by epigenetic lesions?	EZH2
26077423	10.2217/epi.15.14	2015	Small molecule inhibitors of EZH2: the emerging translational landscape.	EZH2
26110843	10.1186/1471-2164-16-S8-S5	2015	Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer.	EZH2
26189108	10.1016/j.leukres.2015.06.005	2015	Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.	EZH2
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	EZH2
26268310	10.1186/s13046-015-0191-0	2015	EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.	EZH2
26280220	10.1038/labinvest.2015.104	2015	Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma.	EZH2
26297264	10.1016/j.clml.2015.02.035	2015	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.	EZH2
26300989	10.1186/s13148-015-0118-9	2015	Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.	EZH2
26371046	10.3390/genes6030812	2015	Epigenetic Heterogeneity of B-Cell Lymphoma: DNA Methylation, Gene Expression and Chromatin States.	EZH2
26458440	10.11406/rinketsu.56.2015	2015	[Epigenetic therapy for hematologic malignancies].	EZH2
26473533	10.1038/bcj.2015.89	2015	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	EZH2
26506391	10.3390/genes6041076	2015	Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers.	EZH2
26517694	10.1172/JCI80325	2015	Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.	EZH2
26637768	10.1182/asheducation-2015.1.522	2015	Advances in therapies for non-Hodgkin lymphoma in children.	EZH2
24097338	10.1038/leu.2013.288	2014	EZH2 in normal and malignant hematopoiesis.	EZH2
24153014	10.1038/leu.2013.307	2014	Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma.	EZH2
24162788	10.3324/haematol.2013.094474	2014	Early lesions of follicular lymphoma: a genetic perspective.	EZH2
24304372	10.3109/10428194.2013.858816	2014	Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.	EZH2
24327543	10.1002/gcc.22126	2014	Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.	EZH2
24355555	10.1016/j.gene.2013.12.006	2014	Identification and characterization of microRNAs in the crab-eating macaque (Macaca fascicularis) using transcriptome analysis.	EZH2
24362818	10.1038/ng.2856	2014	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.	EZH2
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	EZH2
24504051	10.18632/oncotarget.1449	2014	ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.	EZH2
24563539	10.1158/1535-7163.MCT-13-0773	2014	Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.	EZH2
24634383	10.1158/1078-0432.CCR-13-1597	2014	EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.	EZH2
24697523	10.1111/bph.12708	2014	YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.	EZH2
24710217	10.1038/ncomms4630	2014	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.	EZH2
24736461	10.4161/cc.27757	2014	MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.	EZH2
24767850	10.1016/j.bmcl.2014.04.010	2014	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.	EZH2
24785273		2014	[Phenotypic genetic regulation and treatment of malignant lymphoma].	EZH2
24802772	10.1182/blood-2012-12-473439	2014	A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.	EZH2
24811343	10.1038/leu.2014.126	2014	FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.	EZH2
24857928	10.1158/1078-0432.CCR-14-0629	2014	Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?	EZH2
24870942	10.1007/s00277-014-2116-y	2014	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.	EZH2
24900844	10.1021/ml400494b	2014	Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2.	EZH2
24942941	10.3960/jslrt.54.3	2014	Pathology of follicular lymphoma.	EZH2
24942943	10.3960/jslrt.54.23	2014	Molecular pathogenesis of follicular lymphoma.	EZH2
24987060	10.1158/1078-0432.CCR-13-2499	2014	Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.	EZH2
25149548	10.1016/j.humpath.2014.07.002	2014	Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.	EZH2
25154026	10.1021/cb500548b	2014	Reaction coupling between wild-type and disease-associated mutant EZH2.	EZH2
25179367	10.1093/jb/mvu054	2014	Targeting histone methyltransferase EZH2 as cancer treatment.	EZH2
25253781	10.1158/1535-7163.MCT-13-0876	2014	A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.	EZH2
25266721	10.1074/jbc.M114.574517	2014	c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells.	EZH2
25275047		2014	Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.	EZH2
25369470	10.1021/jm501230c	2014	Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.	EZH2
25457120	10.1016/j.chembiol.2014.11.003	2014	Chemical cryptology of cancer's histone code.	EZH2
25457180	10.1016/j.chembiol.2014.09.017	2014	EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.	EZH2
25493630	10.1371/journal.pone.0111840	2014	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.	EZH2
25941598	10.4161/21624011.2014.970025	2014	Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma.	EZH2
23298878	10.1097/MOH.0b013e32835d82fe	2013	Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.	EZH2
23361872	10.1002/cncy.21262	2013	EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.	EZH2
23529930	10.1182/blood-2012-08-450494	2013	EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.	EZH2
23538750	10.1038/leu.2013.94	2013	Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.	EZH2
23614352	10.1021/cb400133j	2013	An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.	EZH2
23680141	10.1016/j.ccr.2013.04.028	2013	EZH2: an epigenetic gatekeeper promoting lymphomagenesis.	EZH2
23759589	10.4161/cc.25163	2013	Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.	EZH2
23948956	10.1007/s00428-013-1428-y	2013	In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.	EZH2
23982173	10.1182/blood-2013-02-484055	2013	Polycomb repressive complex 2 (PRC2) suppresses EÎ¼-myc lymphoma.	EZH2
24052547	10.1182/blood-2013-04-496893	2013	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	EZH2
24107828	10.4161/epi.26546	2013	A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.	EZH2
24122997		2013	Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.	EZH2
24183969	10.1016/j.chembiol.2013.09.013	2013	Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.	EZH2
24200695	10.1172/JCI70626	2013	Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.	EZH2
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	EZH2
24367611	10.1371/journal.pone.0083737	2013	Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.	EZH2
21877899	10.3109/10428194.2011.618235	2012	Update on cytogenetic and molecular changes in myelodysplastic syndromes.	EZH2
22237106	10.1038/nature10725	2012	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.	EZH2
22237151	10.1038/nm.2651	2012	Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.	EZH2
22238326	10.1182/blood-2011-10-388470	2012	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.	EZH2
22323599	10.1073/pnas.1116418109	2012	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).	EZH2
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	EZH2
22431509	10.1101/gad.186411.111	2012	A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.	EZH2
22508723	10.1101/gad.191163.112	2012	A complex Polycomb issue: the two faces of EZH2 in cancer.	EZH2
22520951	10.1016/j.humpath.2011.12.019	2012	Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.	EZH2
22850114	10.1016/j.febslet.2012.07.066	2012	A687V EZH2 is a gain-of-function mutation found in lymphoma patients.	EZH2
22872916		2012	Does the proliferation of human lymphoma cells depend on the mutation of EZH2 and consequential epigenetic modification of H3K27?	EZH2
22932665	10.1158/1078-0432.CCR-12-0873	2012	Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.	EZH2
22956625	10.1258/ebm.2012.012075	2012	Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.	EZH2
23011159	10.3233/CBM-2012-0269	2012	Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung.	EZH2
23023262	10.1038/nchembio.1084	2012	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.	EZH2
23023713	10.1172/JCI63186	2012	Pathogenesis of follicular lymphoma.	EZH2
23051747	10.1038/nature11606	2012	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.	EZH2
23075734		2012	Overexpression of enhancer of zests homolog 2 in lymphoma.	EZH2
23079660	10.1016/j.ccr.2012.09.003	2012	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.	EZH2
23086691	10.1634/theoncologist.2012-0218	2012	Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?	EZH2
23153531	10.1016/j.ccr.2012.10.016	2012	Epigenetic therapy leaps ahead with specific targeting of EZH2.	EZH2
23236167	10.1073/pnas.1210371110	2012	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.	EZH2
20863566	10.1016/j.leukres.2010.08.018	2011	Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias.	EZH2
21087793	10.1016/j.leukres.2010.10.014	2011	Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma.	EZH2
21190999	10.1182/blood-2010-11-321208	2011	Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.	EZH2
21228036	10.3324/haematol.2010.028605	2011	Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.	EZH2
21233829	10.1038/leu.2010.311	2011	EZH2 Y641 mutations in follicular lymphoma.	EZH2
21275949	10.1111/j.1365-2141.2010.08445.x	2011	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas.	EZH2
21367748	10.1158/1078-0432.CCR-10-2156	2011	Aberrations of EZH2 in cancer.	EZH2
21856302	10.1016/j.febslet.2011.08.018	2011	The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.	EZH2
21921784	10.1097/PAS.0b013e318224d2cd	2011	Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins.	EZH2
22194861	10.1371/journal.pone.0028585	2011	EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.	EZH2
20081860	10.1038/ng.518	2010	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.	EZH2
20104248	10.1038/ng0210-100	2010	Deregulation of H3K27 methylation in cancer.	EZH2
20558579	10.2353/ajpath.2010.090769	2010	Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.	EZH2
20565746	10.1186/1476-4598-9-151	2010	Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines.	EZH2
20736451	10.1182/blood-2010-04-280149	2010	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.	EZH2
20858097	10.3109/10428194.2010.510897	2010	Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma.	EZH2
21078963	10.1073/pnas.1012525107	2010	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.	EZH2
19197161	10.4161/cc.8.4.7599	2009	Repressing the repressor: a new mode of MYC action in lymphomagenesis.	EZH2
19657361	10.1038/leu.2009.161	2009	Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.	EZH2
19749796	10.1038/onc.2009.273	2009	Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin.	EZH2
20193471		2009	[Recent advances on EZH2 in malignant tumors].	EZH2
18713946	10.1182/blood-2008-03-147645	2008	MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.	EZH2
17563396	10.1200/JCO.2006.08.7999	2007	Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors.	EZH2
16361539	10.1158/1078-0432.CCR-05-1047	2005	Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.	EZH2
14982841	10.1016/S0002-9440(10)63175-6	2004	Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines.	EZH2
14532106	10.1093/emboj/cdg542	2003	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.	EZH2
11298590	10.1046/j.1365-2141.2001.02641.x	2001	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.	EZH2
11389032	10.1182/blood.v97.12.3896	2001	Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.	EZH2
10980109	10.1016/S0002-9440(10)64583-X	2000	Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.	EZH2
